Citi raised the firm’s price target on Cooper Companies to $430 from $372 and keeps a Buy rating on the shares. Most Q4 results in medical technology met expectations, which bodes well for the sector, the analyst tells investors in a research note. The analyst says the group has historically "worked" in a beat and raise environment and historically has been "recessionary resistant."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on COO:
- Needham med tech analyst to hold an analyst/industry conference call
- Cooper Companies management to meet with Piper Sandler
- Early notable gainers among liquid option names on March 3rd
- Cooper Companies price target raised to $385 from $371 at Baird
- Cooper Companies price target raised to $390 from $385 at Mizuho
